PHARMACOKINETICS
Absorption: approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
Volume of distribution: 9 to 12 L
Protein binding: about 3%
Metabolism: only a small fraction of the drug is metabolized (less than 5%)
Route of elimination: Urinary excretion is the main route of elimination via glomerular filtration.
Half life: 3 hours
Clearance: 110 - 116 mL/min

PHARMACODYNAMIC
Tranexamic acid is antifibrinolytic hemostatic agent that binds to plasminogen in blood clotting pathway to prevent it from interacting with fibrin and stabilizes clot and prevent blood loss.

Menorrhagia & Metrorrhagia: 1300 mg TID for up to 5 days during menstruation.
Post-surgical Bleeding
Post-partum Hemorrhage
Post IUCD Bleeding
Placental Absorption
Conization of Cervix: 1 g IV during the procedure followed by 1 g oral three times a day for 14 days, or 1.5 g every 8 hours the evening after the procedure for 12 days.
Epistaxis
Dental Bleeding: IV 10 mg/kg immediately before surgery, then oral 10 mg/kg 3 to 4 times daily.
Orthopedic Surgery
Urinary Tract Surgery

Nausea
Vomiting
Diarrhoea
Muscle pain
Hives
Rash
Itching
Difficulty breathing or swallowing

Concomitant use of Tranexamic with Factor IX complex concentrates, anti-inhibitor coagulant concentrates or all-trans retinoic acid (oral tretinoin) may increase the risk of thrombosis. Visual or ocular adverse effects may occur.
Cerebral edema and cerebral infarction may be caused in women with subarachnoid hemorrhage.